-
公开(公告)号:EP3169707A4
公开(公告)日:2018-01-24
申请号:EP15818722
申请日:2015-07-09
申请人: UNIV CALIFORNIA
发明人: LIU BIN
IPC分类号: C07K16/30 , A61K31/47 , A61K31/7088 , A61K47/50 , A61K47/68 , A61K49/00 , C07K16/00 , C07K16/28 , C40B40/10 , G01N33/533 , G01N33/574 , G01N33/68
CPC分类号: C07K16/30 , A61K45/06 , A61K47/484 , A61K47/48438 , A61K47/48569 , A61K47/6801 , A61K47/6851 , A61K47/6889 , A61K49/00 , C07K16/005 , C07K16/2866 , C07K16/3069 , C07K2317/10 , C07K2317/21 , C07K2317/32 , C07K2317/622 , C07K2317/73 , C07K2317/77 , C12N15/1037 , G01N33/574 , G01N33/6854
摘要: Methods are provided for identifying and selecting antibodies that are internalized into cells via the macropinocytosis pathway. Additionally antibodies that are internalized via this pathway are provided as well as immunoconjugates comprising such antibodies.
-
公开(公告)号:EP3103811A4
公开(公告)日:2017-11-29
申请号:EP15743456
申请日:2015-02-03
申请人: NAT CANCER CENTER , UNIV TOKYO , RIKEN , NANOCARRIER CO LTD
发明人: MATSUMURA YASUHIRO , YASUNAGA MASAHIRO , KOGA YOSHIKATSU , YAMAMOTO YOSHIYUKI , SATO RYUTA , TSUMURA RYO , KATAOKA KAZUNORI , NISHIYAMA NOBUHIRO , MIURA YUTAKA , MANABE SHINO , KATO YASUKI
CPC分类号: C07K16/36 , A61K39/3955 , A61K47/48438 , A61K47/48561 , A61K47/6817 , A61K47/6849 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/77 , C07K2317/92
摘要: The present invention provides novel antibodies against tissue factor. The present invention also provides pharmaceutical compositions in which an antibody is used as a target-binding factor. Antibodies according to the present invention can exhibit an ability to be internalized into cells expressing tissue factor.
-
公开(公告)号:EP3229846A1
公开(公告)日:2017-10-18
申请号:EP15866409.4
申请日:2015-12-08
发明人: ZHU, Tong , CHEN, Gang , FU, Yanwen , GROS, Edwige
CPC分类号: C07K16/40 , A61K47/48407 , A61K47/48438 , A61K47/48646 , A61K47/6803 , A61K47/6809 , A61K47/6849 , A61K2039/505 , C07K16/2863
摘要: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a c-Met target conjugated at both Cys sites in the hinge region of an IgG antibody. There is further disclosed a method for treating a breast cancer comprising providing an effective amount of a c-Met ADC.
摘要翻译: 公开了具有IgG抗体的抗体药物偶联物(ADC),其结合IgG抗体的铰链区的两个Cys位点处缀合的c-Met靶标。 还公开了治疗乳腺癌的方法,包括提供有效量的c-Met ADC。
-
公开(公告)号:EP2655418B1
公开(公告)日:2017-10-04
申请号:EP11810734.1
申请日:2011-12-19
IPC分类号: C07K16/30 , A61K39/395 , A61P35/00
CPC分类号: A61K47/6851 , A61K31/7068 , A61K38/08 , A61K39/39558 , A61K45/06 , A61K47/48438 , A61K47/48569 , A61K47/48638 , A61K47/6803 , A61K47/6849 , A61K51/1027 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K16/30 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/574 , G01N33/57423 , G01N33/57438 , G01N33/57442 , G01N33/57449 , G01N2333/705
摘要: The invention provides anti-mesothelin antibodies and immunoconjugates and methods of using the same.
-
公开(公告)号:EP2914633A4
公开(公告)日:2016-07-06
申请号:EP13850731
申请日:2013-10-30
发明人: LEUSCHNER CAROLA , ALILA HECTOR
IPC分类号: A61K47/48 , A61K39/395 , A61K47/42 , A61P35/00 , C07K14/00 , C07K16/28 , C07K16/32 , C07K16/44
CPC分类号: C07K7/08 , A61K38/00 , A61K47/48438 , A61K47/48561 , A61K47/6817 , A61K47/6849 , C07K16/2887 , C07K16/3015 , C07K16/3069 , C07K16/32 , C07K2317/524 , C07K2317/526 , C07K2317/622 , C07K2319/74
摘要: The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target.
-
公开(公告)号:EP3191502A4
公开(公告)日:2018-04-25
申请号:EP15839347
申请日:2015-09-10
申请人: SEATTLE GENETICS INC
CPC分类号: C07K7/06 , A61K45/06 , A61K47/484 , A61K47/48438 , A61K47/48561 , A61K47/545 , A61K47/6415 , A61K47/6817 , A61K47/6849 , A61K47/6889 , C07H15/26 , C07K5/1024 , C07K7/02 , C07K16/2875 , C07K16/2878 , C07K16/2881 , C07K2317/24
摘要: Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.
-
公开(公告)号:EP3129052A4
公开(公告)日:2017-11-15
申请号:EP15775944
申请日:2015-04-07
申请人: SEATTLE GENETICS INC
发明人: ZHAO BAITENG , ALBERTSON TINA , HAN TAE
IPC分类号: A61K39/395 , A61K47/42 , C07K16/28
CPC分类号: A61K47/48438 , A61K47/4863 , A61K47/6817 , A61K47/6867 , A61K2039/545 , C07K16/2803 , C07K16/3061 , C07K2317/24
摘要: Methods of optimal dosing of CD19-antibody drug conjugates are disclosed.
-
公开(公告)号:EP3218005A1
公开(公告)日:2017-09-20
申请号:EP15859152.9
申请日:2015-11-12
发明人: DA SILVA, Ana Paula Galvao , GHADERI, Darius , ZHANG, Mai , MEETZE, Kristan , DESANDER, Julie , BEHRENS, Jeffrey , EAVARONE, David A. , PRENDERGAST, Jillian M. , LUGOVSKOY, Alexey Alexandrovich
IPC分类号: A61K39/395 , A61K39/00 , C07K16/00
CPC分类号: G01N33/57492 , A61K47/48438 , A61K47/48569 , C07K16/005 , C07K16/3076 , C07K16/44 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92
摘要: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.
摘要翻译: 本发明提供了聚糖相互作用抗体以及用于产生可用于治疗和预防人类疾病(包括癌症)的聚糖相互作用抗体的方法。 此类与聚糖相互作用的抗体包括单克隆抗体,其衍生物和片段以及包含它们的组合物和试剂盒。 进一步提供了使用聚糖相互作用抗体靶向细胞和治疗疾病的方法。
-
9.
公开(公告)号:EP3052525A4
公开(公告)日:2017-03-29
申请号:EP14850812
申请日:2014-10-02
申请人: VIVENTIA BIO INC
IPC分类号: C07K16/30 , A61K39/395 , A61K49/00 , A61P35/00 , C07K14/21 , C07K14/415 , C07K16/46 , C07K19/00 , G01N33/574
CPC分类号: C07K16/30 , A61K39/39558 , A61K45/06 , A61K47/48438 , A61K47/48446 , A61K47/48484 , A61K47/48569 , A61K47/6817 , A61K47/6819 , A61K47/6829 , A61K47/6851 , A61K49/0002 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/92 , C07K2319/55 , G01N33/574
摘要: The present disclosure is related to compositions of antibodies and immunoconjugates that potentially lack T-cell epitopes and elicit reduced immune response. The antibody may be an antibody fragment, such as Fab, Fab′, F(ab′)2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments, multimers, and any combination thereof. In a further embodiment, the antibody may bind to an antigen epithelial cell adhesion molecule (EpCAM). In another embodiment, an immunoconjugate may comprise an antibody attached to an effector molecule, wherein the effector molecule may be a radioisotope, an antineoplastic agent, an immunomodulator, a biological response modifier, lectin, a toxin, a chromophore, a fluorophore, a chemiluminescent compound, an enzyme, a metal ion, and any combination thereof.
摘要翻译: 本公开涉及可能缺乏T细胞表位并引发降低的免疫应答的抗体和免疫缀合物的组合物。 抗体可以是抗体片段,例如Fab,Fab',F(ab')2,scFv,dsFv,ds-scFv,二聚体,小体抗体,双抗体,双特异性抗体片段,多聚体及其任何组合。 在另一个实施方案中,抗体可以结合抗原上皮细胞粘附分子(EpCAM)。 在另一个实施方案中,免疫偶联物可以包含附着于效应分子的抗体,其中效应分子可以是放射性同位素,抗肿瘤剂,免疫调节剂,生物反应调节剂,凝集素,毒素,发色团,荧光团,化学发光 化合物,酶,金属离子及其任何组合。
-
10.
公开(公告)号:EP2887959A4
公开(公告)日:2016-03-23
申请号:EP13831502
申请日:2013-08-23
申请人: AGENSYS INC , SEATTLE GENETICS INC
CPC分类号: C07K16/30 , A61K45/06 , A61K47/48415 , A61K47/48438 , A61K47/48569 , A61K47/48584 , A61K47/48592 , A61K47/486 , A61K47/48607 , A61K47/48623 , A61K47/6811 , A61K47/6817 , A61K47/6851 , A61K47/6855 , A61K47/6857 , A61K47/6859 , A61K47/6861 , A61K47/6865 , A61K2039/505 , C07K16/18 , C07K16/3015 , C07K16/3023 , C07K16/3038 , C07K16/3053 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , A61K39/395 , A61K2300/00
摘要: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
-
-
-
-
-
-
-
-
-